Duration in first-time users can be represented as a PK→PD modeling context in which initial-use differences are encoded strictly as parameter-set variations in absorption rate, distribution kinetics, metabolic turnover, elimination geometry, and PD persistence mapping. Duration is the modeled interval during which concentration remains above a defined PD persistence region, rather than a clinical measure. Sildenafil and tadalafil can occupy different modeled persistence geometries: sildenafil can be represented with a comparatively steeper concentration rise and shorter decline, while tadalafil can be represented with a slower rise and longer decline. First-time-use parameter sets therefore expand the PK/PD parameter space without implying behavioral, experiential, or clinical outcomes. Duration differences are geometric properties of concentration–time trajectories and their mapping into a persistence region. This framework separates the timing of exposure from the mathematical definition of persistence and avoids treating first-time use as a clinical category. Link to duration vs onset balance.
PK determinants shape modeled duration through the geometry of exposure before and during the concentration decline. Absorption rate controls how quickly the concentration–time trajectory develops, so different parameter sets can alter the early slope and peak position without defining the terminal persistence interval. Distribution kinetics can modify the transition between early and later concentration phases, while metabolic turnover influences the rate at which active compound is removed or transformed. Elimination rate then defines much of the declining geometry: a lower rate constant produces a slower concentration decrease, whereas a higher rate constant produces a steeper decrease. Two parameter sets can therefore share identical absorption parameters yet generate different persistence intervals because elimination parameters differ. Tmax and Cmax describe peak geometry but neither quantity alone defines duration. This separation keeps onset, peak exposure, and persistence as distinct coordinates within the same PK trajectory. Link to absorption curves and tmax comparison.
PD mapping determines how a concentration trajectory is translated into a persistence interval after exposure approaches the persistence region. A PD threshold, response function, or coupling parameter can establish the concentration coordinate at which persistence is considered present within the model. First-time-use PD variability can therefore shift threshold placement or alter coupling while leaving the underlying PK trajectory unchanged. Identical sildenafil or tadalafil concentration–time curves could consequently map to different duration coordinates when the PD parameter set differs. Conversely, different PK trajectories could converge on similar duration coordinates if their PD mappings compensate geometrically. This describes how an exposure trajectory is converted into a persistence interval. The distinction is important because PK variability changes the concentration curve itself, while PD variability changes how that curve is interpreted. Duration in first-time users is therefore a PK→PD persistence construct, not a behavioral or experiential category. Link to pd variability and pkpd summary.
First-time-use absorption variability can be represented by changes in the absorption rate constant, lag structure, input duration, or other parameters controlling the entry of compound into the systemic compartment. These changes modify the rising limb of the concentration–time curve and can shift the timing and magnitude of early exposure. A faster input process produces a steeper ascent, while a slower input process spreads the same nominal input across a broader time interval. Duration is not determined by the rising limb alone, but altered absorption geometry can change the concentration level from which the subsequent decline begins. Consequently, two parameter sets can share the same elimination rate while producing different persistence intervals because their starting trajectories differ. In this framework, first-time use simply identifies a parameter set within a modeled variability space. The category does not encode behavior, experience, or clinical response; it specifies only alternative PK input geometry. Link to absorption rate.
Distribution and metabolic turnover parameters influence the later portions of the concentration–time trajectory and therefore modify persistence geometry. Distribution kinetics can determine how rapidly concentration moves between compartments, changing the shape of the intermediate decline without requiring a change in total administered amount. Metabolic turnover parameters describe transformation processes that remove parent compound or generate downstream species, while elimination parameters control the net rate at which measurable exposure decreases. A slower turnover or elimination process can produce a more extended concentration tail, whereas faster removal produces a steeper decline. The resulting duration coordinate depends on where that trajectory intersects the defined PD persistence region. First-time-use variability can therefore be modeled as alternative parameter combinations rather than as a separate behavioral state. This approach keeps distribution, metabolism, and elimination mechanistically distinct while allowing them to interact within one PK model. Link to pk variability.
| PK Domain | Mechanistic Determinant | Link |
|---|---|---|
| Absorption | Early exposure geometry. | absorption curves |
| Distribution & Metabolism | Persistence geometry. | pk variability |
A PD persistence threshold defines the concentration or modeled response region used to mark the duration coordinate. First-time-use variability can be represented by changes in threshold location, maximum response, slope, or other concentration–effect parameters. With a lower modeled persistence threshold, a fixed concentration–time trajectory remains within the persistence region for a longer modeled interval; with a higher threshold, the same trajectory exits that region earlier. This is a mathematical mapping operation rather than a statement about a clinical effect. The PK curve remains unchanged when only the PD parameter set changes, but the duration coordinate can move because the concentration–effect relationship has changed. Thus, first-time-use variability can be represented by multiple PD parameter sets applied to the same sildenafil or tadalafil PK trajectory. The resulting duration spread reflects alternative threshold mappings within the model. Link to pd variability.
PD variability can modify duration even when the underlying PK trajectory is held constant. Suppose two parameter sets receive the same concentration–time curve, including identical absorption, distribution, metabolism, and elimination values. If their PD mappings assign different persistence thresholds or concentration–effect slopes, the time at which each trajectory crosses its persistence boundary can differ. The PK geometry is therefore identical, while the modeled duration coordinate is not. Conversely, different PK trajectories can yield similar duration values if their PD mappings place persistence boundaries at compensating locations. This separation allows duration to be decomposed into exposure geometry and effect-mapping geometry rather than treated as a single property of the drug concentration curve. First-time use does not create a special PD mechanism; it provides a context in which alternative parameter sets can be represented and compared mathematically. Link to pkpd summary.
| PD Domain | Mechanistic Determinant | Link |
|---|---|---|
| Persistence Threshold | Concentration–effect mapping. | pd variability |
| PD Variability | Duration differences. | pkpd summary |
PK trajectories determine persistence geometry through the sequence of absorption, distribution, metabolism, and elimination processes. In a first-time-use parameter-set framework, each trajectory can be represented by distinct rate constants or compartment parameters while retaining the same structural model. A faster absorption process changes the ascending limb, distribution parameters reshape intermediate phases, and elimination parameters control the terminal decline. The modeled duration coordinate emerges when the resulting concentration trajectory intersects the PD persistence region. Sildenafil and tadalafil can therefore be represented by different combinations of absorption and decline parameters, producing distinct geometric profiles without introducing behavioral or experiential variables. Speed and duration remain separate dimensions: a trajectory can rise quickly yet decline quickly, or rise more gradually and decline more slowly. The model captures these relationships through rate parameters rather than through subjective descriptions. Link to speed profiles.
PD mapping determines where the persistence boundary is placed relative to a PK concentration–time trajectory. A concentration–effect function can use parameters such as threshold location, slope, maximum response, or coupling coefficients to translate exposure into a modeled persistence region. If the boundary is shifted while the PK curve remains fixed, the crossing time changes without any alteration to absorption, distribution, metabolism, or elimination. This demonstrates why onset-related coordinates and duration-related coordinates should not be treated as interchangeable. The same PK trajectory can have one onset coordinate and multiple modeled persistence coordinates under different PD parameter sets. For sildenafil and tadalafil, the distinction allows duration geometry to be analyzed independently from the initial rise of concentration. First-time-use variability is therefore represented as variation in parameter values within the PK→PD mapping, not as an experiential classification. Link to onset difference.
PK and PD variability interact because PK parameters determine the concentration trajectory while PD parameters determine how that trajectory is translated into a persistence interval. A first-time-use parameter set may combine faster or slower absorption, different distribution kinetics, alternative metabolic turnover, and distinct elimination rates with a separate PD threshold or coupling function. The resulting duration coordinate is produced by the intersection of these two geometries. Changes in PK can move the concentration curve, while changes in PD can move the persistence boundary. Their combined effect can enlarge or narrow the modeled range of duration without requiring any change in the structural PK→PD framework. Sildenafil and tadalafil can thus be compared by holding selected parameters constant and varying others, isolating the contribution of each domain. The interpretation remains mechanistic: duration is a coordinate generated by exposure and persistence mapping, not a statement about real-world effectiveness or experience. Link to duration vs onset balance.
| Balance Domain | Mechanistic Determinant | Link |
|---|---|---|
| PK Trajectory | Exposure development. | speed profiles |
| PD Mapping | Threshold placement. | onset difference |
| PK→PD Balance | Combined geometry. | duration vs onset balance |
Duration in first-time users can be represented as the time interval between two model-defined coordinates on a PK→PD trajectory: entry into a persistence region and exit from that region. The concentration–time curve supplies the PK geometry, while the PD mapping supplies the boundary used to identify persistence. First-time use is represented only by alternative parameter values within this framework. For example, one parameter set can specify a particular absorption rate, distribution pattern, metabolic turnover, and elimination constant, while another set uses different values. The resulting curves can cross the same PD boundary at different times. Duration is therefore a derived coordinate rather than a standalone PK parameter. It does not require a behavioral or experiential category. The model can also separate rising-phase timing from declining-phase persistence, allowing onset and duration to occupy different regions of the same trajectory. This provides a strictly mechanistic representation of first-time-use variability.
PK parameters shape first-time-use duration by controlling the geometry of the concentration–time curve. Absorption parameters determine the input rate and the rising limb, distribution parameters influence movement between modeled compartments, and metabolic turnover parameters affect the persistence of parent or downstream species. Elimination rate controls the declining portion of exposure and therefore strongly influences the time required for concentration to cross a defined persistence boundary. Different parameter combinations can produce different duration coordinates even when the administered amount is held constant. Tmax and Cmax describe peak timing and peak magnitude, but they do not independently define the duration interval. A model can therefore vary absorption while holding elimination constant, or vary elimination while holding absorption constant, to isolate their geometric contributions. First-time use is simply a context for selecting alternative parameter sets. It does not introduce a separate PK process, behavioral mechanism, or experiential variable into the model.
PD parameters influence first-time-use duration by defining how concentration is translated into a persistence region. A threshold parameter can specify the concentration boundary, while slope and coupling parameters can determine how sharply the modeled response changes around that boundary. When the PK concentration–time curve is fixed, changing the PD parameter set can move the calculated crossing time and therefore change the modeled duration. The PK trajectory itself remains unchanged. This distinction separates exposure geometry from concentration–effect mapping. A lower persistence boundary can produce a later modeled exit from the persistence region, while a higher boundary can produce an earlier exit, assuming the same declining trajectory. Such differences are mathematical consequences of the chosen PD mapping. First-time-use variability can therefore be represented by alternative PD parameter sets applied to identical PK trajectories, without treating first-time users as a behavioral, experiential, or clinical subgroup.
Sildenafil and tadalafil can be represented by different first-time-use duration geometries because their PK parameter sets can generate different concentration–time trajectories. In a mechanistic model, sildenafil may be represented with a steeper rising phase and faster decline, while tadalafil may be represented with a slower rising phase and slower decline. These are trajectory descriptors rather than statements about clinical effects. Duration is obtained by mapping each trajectory through a defined PD persistence function and locating the relevant boundary crossing. Changes in absorption, distribution, metabolic turnover, or elimination can shift that crossing, as can changes in PD threshold or coupling parameters. Thus, the comparison is not a single fixed duration value attached to each drug. It is a comparison of parameterized trajectories and their persistence mappings. First-time use simply allows alternative parameter sets to be examined within the same PK→PD structure.
PK→PD variability expands duration interpretation by allowing the concentration trajectory and the persistence mapping to vary independently or together. PK variability can change absorption geometry, distribution timing, metabolic turnover, and elimination rate, moving the concentration curve itself. PD variability can change threshold placement or concentration–effect coupling, moving the persistence boundary relative to that curve. When both domains vary, the modeled duration becomes a function of multiple parameters rather than a single fixed property. This makes it possible to distinguish whether a duration difference originates mainly from exposure geometry, PD mapping, or their interaction. First-time use does not need to be assigned a behavioral meaning in this framework. It is represented as a set of possible PK and PD parameter combinations within a defined model structure. The resulting duration coordinates are therefore mathematical outputs of parameter selection and curve-boundary intersections, not claims about real-world effectiveness or patient experience.